This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Minden, S Articles by Outley, J Search for Related Content PubMed PubMed Citation Articles by Minden, S Articles by Outley, J Social Bookmarking                         What's this?

Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study

Brigham and Women’s Hospital, Boston, MA, USA and Abt Associates Inc., Cambridge, MA, USA, sarahminden{at}gmail.com

D Hoaglin

Brigham and Women’s Hospital, Boston, MA, USA and Abt Associates Inc., Cambridge, MA, USA

S Jureidini

Brigham and Women’s Hospital, Boston, MA, USA and Abt Associates Inc., Cambridge, MA, USA

L Hadden

Brigham and Women’s Hospital, Boston, MA, USA and Abt Associates Inc., Cambridge, MA, USA

D Frankel

Brigham and Women’s Hospital, Boston, MA, USA and Abt Associates Inc., Cambridge, MA, USA

Y Komatsuzaki

Brigham and Women’s Hospital, Boston, MA, USA and Abt Associates Inc., Cambridge, MA, USA

J Outley

Brigham and Women’s Hospital, Boston, MA, USA and Abt Associates Inc., Cambridge, MA, USA

Background

Although experts recommend that people with multiple sclerosis (MS) should begin treatment with disease-modifying agents (DMAs) as soon as possible after diagnosis and continue indefinitely, many do not use these agents or discontinue them prematurely. Since DMAs reduce relapse rates and slow disease progression, and since even benign relapses and course can lead to axonal damage and permanent neurologic impairment, it is important that all appropriate candidates have access to treatment. We used a population-based sample of people with MS to determine rates, predictors, and reasons for use, non-use, and discontinuation of DMAs.

Methods

We collected data from 2156 people with MS on their use of and experience with DMAs. We used chi-squared tests to compare current, past, and never users of any DMA and ever users of individual DMAs, and logistic regression to identify predictors of use.

Results

One-half of the participants were using a DMA at the time of the interview; 12.2% had used previously, but stopped. Reasons for never using and reasons for stopping were at odds with expert recommendations. Characterization of users, and of their experiences by type of DMA, was consistent with current knowledge of these agents. Seeing a neurologist for usual MS care was an important factor in starting and persisting with DMA therapy.

Conclusions

Dissemination of expert opinion about, and management strategies for, use of DMAs to non-neurologic professionals and patients and their families might help more people who are appropriate candidates for DMA therapy to start and continue treatment.

Key Words: disease-modifying therapies • multiple sclerosis

Multiple Sclerosis, Vol. 14, No. 5, 640-655 (2008)
DOI: 10.1177/1352458507086463


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?